First Time Loading...

Zoetis Inc
NYSE:ZTS

Watchlist Manager
Zoetis Inc Logo
Zoetis Inc
NYSE:ZTS
Watchlist
Price: 173.98 USD 0.14%
Updated: May 17, 2024

P/E
Price to Earnings

33.2
Current
38.6
Median
23.4
Industry
Lower than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
33.2
=
Market Cap
79.5B
/
Net Income
2.4B
All Countries
Close
Market Cap P/E
US
Zoetis Inc
NYSE:ZTS
79.5B USD 33.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
732.8B USD 119.4
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 45.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
US
Johnson & Johnson
NYSE:JNJ
371.2B USD 9.7
US
Merck & Co Inc
NYSE:MRK
331.4B USD 143.8
UK
AstraZeneca PLC
LSE:AZN
187.7B GBP 37.6
CH
Roche Holding AG
SIX:ROG
188.9B CHF 16.4
CH
Novartis AG
SIX:NOVN
182.4B CHF 11.5
US
Pfizer Inc
NYSE:PFE
161.5B USD -522
Earnings Growth
US
Zoetis Inc
NYSE:ZTS
Average P/E: 52.1
33.2
41%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.4
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.7
-20%
US
Merck & Co Inc
NYSE:MRK
143.8
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.6
168%
CH
Roche Holding AG
SIX:ROG
16.4
26%
CH
Novartis AG
SIX:NOVN
11.5
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -522
680%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
29.7
2-Years Forward
P/E
26.6
3-Years Forward
P/E
24.1

See Also

Discover More